Related Experiment Video
Updated: Jan 8, 2026
06:51
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
13.1K
Ceftazidime-Induced Agranulocytosis: A Case Report
Bingbin Dong1,2, Xin Wu1,3, Changbao Huang1
1Department of Emergency Medicine Yijishan Hospital, First Affiliated Hospital of Wannan Medical College Wuhu China.
Clinical Case Reports
|December 19, 2025
Summary
Ceftazidime can rarely cause severe agranulocytosis, a dangerous drop in white blood cells. Promptly stopping the drug and using G-CSF can help patients recover.
Area of Science:
- Pharmacology
- Hematology
- Internal Medicine
Background:
- Ceftazidime is a common antibiotic.
- Adverse events typically include hypersensitivity and gastrointestinal issues.
- Neutropenia is a rare complication.
Purpose of the Study:
- To report a rare case of ceftazidime-induced agranulocytosis.
- To highlight the importance of considering drug-induced cytopenia.
Main Methods:
- Case presentation of an 89-year-old woman.
- Clinical assessment, imaging, and laboratory tests.
- Exclusion of other causes of neutropenia.
Main Results:
- Patient developed severe neutropenia and agranulocytosis during ceftazidime treatment.
- Cessation of ceftazidime and administration of G-CSF led to hematological recovery.
- Other causes for cytopenia were ruled out.
Conclusions:
- Ceftazidime can induce agranulocytosis, though rarely.
- Clinicians must consider drug-induced cytopenia in differential diagnosis.
- Early drug cessation and G-CSF are crucial for recovery.
